Form D · Other

Slingshot Biosciences, Inc.

Emeryville, CA · CIK 0001867067

Offering snapshot reported Apr 26, 2024 · SEC filing

Reported sold: $26.2M
Investors reported: 10
Minimum accepted: $0
First sale: Jan 24, 2023

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$11,227,334 → $26,227,275
Reported investors8 → 10

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Apr 26, 2024	Amendment	$26,227,275	$14,999,941vs Feb 6, 2023	10	SEC filing
Feb 6, 2023	Initial	$11,227,334	No comparison	8	SEC filing
Jul 23, 2021	Amendment	$22,879,969	No comparison	Not reported	SEC filing
Jun 14, 2021	Initial	$12,379,974	No comparison	Not reported	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-472755

Series A-3 Preferred Stock and the common stock issuable upon conversion thereof.

Source: Form D, filed Apr 26, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Nicolas Barthelemy	Director
Jeffrey Kim	Director, Executive
Andrew Lee	Director
Corey Ritter	Director
Ronald J Silberman	Director
Patrick Weiss	Director
Adam Wieschhaus	Director

Issuer details

Industry: Other (See others in industry)

Address:

1250 45 Th Street, Suite 330
Emeryville, CA, 94608